DRRX Projected Dividend Yield
Durect Corp ( NASDAQ : DRRX )Durect is a biopharmaceutical company developing lifesaving investigational therapies derived from its Epigenetic Regulator Program. Larsucosterol, a chemical entity in clinical development, is the primary candidate in Co.'s Epigenetic Regulator Program. An orally bioavailable small molecule, larsucosterol has been shown in both in vitro and in vivo studies to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival. Co. is developing larsucosterol for alcohol-associated hepatitis, a life-threatening acute liver condition with no approved therapeutics. Co. has also investigated larsucosterol in patients with non-alcoholic steatohepatitis. 20 YEAR PERFORMANCE RESULTS |
DRRX Dividend History Detail DRRX Dividend News DRRX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |